Cordis US
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Cordis US sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Cordis US: 19 sponsored US clinical trials, 1 recruiting.
Cordis US sponsors 19 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 17 completed. 10 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is PAD, with 1 trials.
Top-decile sponsor footprint
Cordis US ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
19 total, page 1 of 1
Mobilization and Outcomes After Venous Closure
NCT07246902
Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression
NCT05554471
A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)
NCT01664078
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
NCT01355406
S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease
NCT00739102
Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device
NCT00345631
SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy
NCT00403078
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
NCT00165035
An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).
NCT00489320
Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)
NCT00231231
NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
NCT00231283
Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
NCT00232752
Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
NCT00232739
Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)
NCT00231257
Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions
NCT00489164
Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)
NCT00231244
Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)
NCT00233688
Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)
NCT00232765
Cordis Bilateral AAA Device Compared to Open Surgical Repair of Abdominal Aortic Aneurysms (ARIBA)
NCT00235118
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 10 |
Where Cordis US enrollment is open (later-stage tilt)
1 recruiting of 19 indexed (5% open); 17 completed (89%).
Phase mix: 10 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: PAD (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cordis US: open-pipeline peers nationwide
Peers matched on 19 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Cordis US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 trials (± recruiting share)
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Defense and Veterans Center for Integrative Pain Management · 19 trials · 5% recruiting
Sponsors near 5% open enrollment (± trial volume)
- DePuy Orthopaedics · 5% recruiting · 38 trials
- Impax Laboratories · 5% recruiting · 19 trials
- Kent State University · 5% recruiting · 19 trials
- Omeros Corporation · 5% recruiting · 19 trials
Related
What to do with this Cordis US page
19 registered trials is a research-attention snapshot, not an endorsement of Cordis US or any single study.
- 1 of Cordis US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- PAD is the condition Cordis US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PAD trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cordis US pipeline card: 19 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.